Read, pause, explore
Tesamorelin
Also listed as Egrifta WR
A reference to read with the sources beside you.
Status as of . The reference fields below define the scope of these labels.
Filed under Hormones for browsing.
Reference fields
Sources for these fields- Approval scope
- Egrifta WR addresses excess abdominal fat in adults with HIV-associated lipodystrophy.
- Route and formulation
- Specified subcutaneous formulation.
- Mechanism
- Stimulates growth-hormone release.
- Evidence
- A randomized trial measured visceral fat.
- Limits of the evidence
- Not for weight management.
- Safety context
- Active malignancy is a contraindication.
A closer reading
Make space for the question
Eligibility rules describe who could enter an investigation; applicability asks how its findings fit another situation. Meeting an entry rule does not settle every question about fit, and missing one rule does not explain which part of the reasoning would change. A practical way to read is to connect each restriction to the question it helps define. Then consider what would need to stay similar for the interpretation to travel. This keeps entry criteria useful without turning them into a complete description of a person or a substitute for examining the circumstances of another setting.
Keep these questions nearby
- What question did each entry restriction help the investigators define more precisely?
- Which features would need to remain similar for the interpretation to apply elsewhere?
- Does meeting the entry rules resolve applicability, or leave other circumstances to consider?
Sources
The references below accompany the entry as a whole. Dates show when each source was checked.
- EGRIFTA WRNLM · Checked
- Falutz trialPubMed · Checked
Keep a little room for reading
Prepared by Healthy Pound Editorial Team. Educational reference; no clinical review is claimed. This page does not provide individual medical advice.